Multi-omics integration reveals a six-malignant cell maker gene signature for predicting prognosis in high-risk neuroblastoma

Yan, Zi-Jun; Liu, Qiming; Cao, Ziyang; Wang, Jinxia; Zhang, Hongyang; Liu, Jiangbin; Zou, Lin

doi:10.3389/fninf.2022.1034793

Cited by 1 publication

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent developments in three-dimensional, microfluidic, and multicellular systems used for neuroblastoma research [ 150 ] are promising, especially for testing new therapeutic approaches [ 118 , 160 , 253 , 254 ], including natural product research [ 177 ], immunotherapy [ 172 , 255 , 256 ], and new multimodal strategies for high-risk neuroblastoma [ 149 ]. A heterogenous disease such as neuroblastoma may largely benefit from comprehensive approaches involving a combination of various biological models supplemented by mathematical simulations [ 146 , 235 , 257 , 258 ]. Such strategies give promise for a better understanding of the malignancy, which may facilitate the development of effective therapies and improve the outcome for patients.…”

Section: Discussionmentioning

confidence: 99%

Preclinical Models of Neuroblastoma—Current Status and Perspectives

Krawczyk

Kitlińska

2023

Cancers

View full text Add to dashboard Cite

Preclinical in vitro and in vivo models remain indispensable tools in cancer research. These classic models, including two- and three-dimensional cell culture techniques and animal models, are crucial for basic and translational studies. However, each model has its own limitations and typically does not fully recapitulate the course of the human disease. Therefore, there is an urgent need for the development of novel, advanced systems that can allow for efficient evaluation of the mechanisms underlying cancer development and progression, more accurately reflect the disease pathophysiology and complexity, and effectively inform therapeutic decisions for patients. Preclinical models are especially important for rare cancers, such as neuroblastoma, where the availability of patient-derived specimens that could be used for potential therapy evaluation and screening is limited. Neuroblastoma modeling is further complicated by the disease heterogeneity. In this review, we present the current status of preclinical models for neuroblastoma research, discuss their development and characteristics emphasizing strengths and limitations, and describe the necessity of the development of novel, more advanced and clinically relevant approaches.

show abstract